Because ID4 alone, as well as the SOX4 and OCT-4 complex, activates SOX2, and because chemoresistance is associated with both SOX2 and ID4 augmented expression, it is possible to speculate that multiple SOX2 activation events in GBM may impair patient prognosis. This evidence concerns the gene SOX4 and glioblastoma.